Maze Therapeutics Inc. has disclosed new sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria, metabolic syndrome, ...
Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.
The world's best clinics achieve success in Parkinson’s treatment by individualizing deep brain stimulation (DBS) through ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback